The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged Therapy
Abstract
The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3′-azido-3′-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4 + HeLa cells. Fifty percent inhibitory dose (ID 50 ) values of 18 isolates from untreated individuals ranged between 0.01 μ M and 0.05 μ M . In contrast, most isolates from patients who had received zidovudine for 6 months or more exhibited decreased sensitivity characterized by changes in ID 50 or ID 95 values (or both), with isolates from several patients (5/15) showing 100-fold increases in ID 50 . The latter isolates were also insensitive to 3′-azido-2′,3′-dideoxyuridine; however, the isolates were still sensitive to 2′,3′-dideoxycytidine, 2′,3′-dideoxy-2′,3′-didehydrothymidine, or phosphonoformate. It cannot be determined from this small sample of patients whether development of a less sensitive virus phenotype results in clinical resistance. Appearance of such variants was not associated with a consistent increase in viral p24 concentrations in patient plasma and did not herald any sudden deterioration in clinical status. More extensive studies are required to determine the clinical significance. Thus, it would be premature to alter any treatment protocols for HIV-infected individuals at present.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a clinical trial, its dramatic short-term effects in delaying the death of AIDS patients (109) led to its rapid approval for use, although the virus rebounded after a few months due to the appearance of mutations in RT that render it AZT resistant (110).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [110]
Citations
Cites
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Fischl, M. A., Richman, D. D., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Schooley, R. T., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170401 · Cited by 2,995
Self-citationThe Toxicity of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., Laskin, O. L., Leedom, J. M., Groopman, J. E., Mildvan, D., Hirsch, M. S., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198707233170402 · Cited by 1,199
Self-citationInfection of HTLV-III/LAV in HTLV-I-Carrying Cells MT-2 and MT-4 and Application in a Plaque Assay
Harada, S., Koyanagi, Y., & Yamamoto, N. (1985) · Science · doi:10.1126/science.2992081 · Cited by 857
Schmitt, F. A., Bigley, J. W., McKinnis, R., Logue, P. E., Evans, R. W., Drucker, J. L., & The AZT Collaborative Working Group* (1988) · New England Journal of Medicine · doi:10.1056/nejm198812153192404 · Cited by 396
Klecker, R. W., Collins, J. M., Yarchoan, R., Thomas, R., Jenkins, J. F., Broder, S., & Myers, C. E. (1987) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1987.49 · Cited by 381
Site-specific mutagenesis of AIDS virus reverse transcriptase
Larder, B. A., Purifoy, D. J. M., Powell, K. L., & Darby, G. (1987) · Nature · doi:10.1038/327716a0 · Cited by 312
Self-citationDevelopment of a sensitive quantitative focal assay for human immunodeficiency virus infectivity
Chesebro, B., & Wehrly, K. (1988) · Journal of Virology · doi:10.1128/jvi.62.10.3779-3788.1988 · Cited by 304
Field, H. J., & Darby, G. (1980) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.17.2.209 · Cited by 242
Self-citationISOLATION AND CHARACTERISATION OF RESISTANT HERPES SIMPLEX VIRUS AFTER ACYCLOVIR THERAPY
Burns, W., Santos, G., Saral, R., Laskin, O., Lietman, P., Mclaren, C., & Barry, D. (1982) · The Lancet · doi:10.1016/s0140-6736(82)91620-8 · Cited by 240
Altered substrate specificity of herpes simplex virus thymidine kinase confers acyclovir-resistance
Darby, G., Field, H. J., & Salisbury, S. A. (1981) · Nature · doi:10.1038/289081a0 · Cited by 204
Self-citation
Cited by
Items 801–900 of 1,000
HP 0.35, a cephalosporin degradation product is a specific inhibitor of lentiviral RNAses H
Hafkemeyer, P., Neftel, K. A., Hobi, R., Pfaltz, A., Lutz, H., Lüthi, K., Focher, F., Spadari, S., & Hübscher, U. (1991) · Nucleic Acids Research · doi:10.1093/nar/19.15.4059 · Cited by 21
Blaise, P., Clevenbergh, P. A., Vaira, D., Moutschen, M. P., & Dellamonica, P. (2002) · Acta Clinica Belgica · doi:10.1179/acb.2002.041 · Cited by 21
Benefits and limitations of testing for resistance to HIV drugs
Richman, D. D. (2004) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkh157 · Cited by 21
Self-citationVaccaro, J. A., & Anderson, K. S. (1998) · Biochemistry · doi:10.1021/bi9810353 · Cited by 21
Reichman, R. C., Tejani, N., Lambert, J. L., Strussenberg, J. G., Bonnez, W., Blumberg, B. M., Epstein, L. G., & Dolin, R. (1993) · Antiviral Research · doi:10.1016/0166-3542(93)90071-p · Cited by 21
Dubreuil, M., Sportza, L. M., D’Addario, M., Lacoste, J., Rookie, R., Wainberg, M. A., & Hiscotti, J. (1990) · Virology · doi:10.1016/0042-6822(90)90306-c · Cited by 21
Kinase bypass: A new strategy for anti-HIV drug design
McGuigan, C., Kinchington, D., Nicholls, S. R., Nickson, C., & OʼConnor, T. J. (1993) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/s0960-894x(00)80316-9 · Cited by 21
Loss of Synergistic Response to Combinations Containing AZT in AZT-Resistant HIV-1
Cox, S. W., Albert, J., Wahlberg, J., Uhlén, M., & Wahrén, B. (1992) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1992.8.1229 · Cited by 21
Tuntland, T., Ravasco, R. J., Al-Habet, S. M. H., & Unadkat, J. D. (1994) · Pharmaceutical Research · doi:10.1023/a:1018928013044 · Cited by 21
Sheehy, N., & Desselberger, U. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-2-223 · Cited by 21
Buckheit, R. W., White, E. L., Decker, J. M., Allen, L. B., Ross, L. J., Shannon, W. M., Janssen, P. A. J., & Chirigos, M. A. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500105 · Cited by 21
Antiretroviral resistance testing in HIV-positive people
Aves, T., Tambe, J., Siemieniuk, R. A. C., & Mbuagbaw, L. C. E. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006495.pub5 · Cited by 20
Schwartz, A. M., McCrackin, M. A., Schinazi, R. F., Hill, P. B., Vahlenkamp, T. W., Tompkins, M. B., & Hartmann, K. (2014) · American Journal of Veterinary Research · doi:10.2460/ajvr.75.3.273 · Cited by 20
Inhibition of HIV-1 Reverse Transcriptase by Aryl-Substituted Naphto- and Anthraquinones
Ilina, T. V., Семенова, Е. А., Tr, P., Покровский, А. Г., Nechepurenko, I. V., Shults, E. E., Andreeva, O. I., Kochetkov, S. N., & Толстиков, Г. А. (2002) · Doklady Biochemistry and Biophysics · doi:10.1023/a:1014467509828 · Cited by 20
Protease inhibitors: A new weapon and a new strategy against HIV
Phillips, K. D. (1996) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/s1055-3290(96)80049-5 · Cited by 20
Update on the laboratory diagnosis and monitoring of HIV infection
Constantine, N. T., Kabat, W. J., & Zhao, Y. (2005) · Cell Research · doi:10.1038/sj.cr.7290361 · Cited by 20
Buckheit, R. W., Decker, J. M., Qualls-Goodwin, K., Bowdon, B. J., & Shannon, W. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.17.8361 · Cited by 20
Mathé, G., Pontiggia, P., Bourut, C., Chenu, E., & Orbach-Arbouys, S. (1994) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(94)90075-2 · Cited by 20
Rübsamen‐Waigmann, H., Schröder, B., BIESERT, L., Cd, B., von Briesen, H., Suhartono, H., Zimmermann, F., Brede, H. D., Regeniter, A., Staszewski, S., et al. (1991) · Infection · doi:10.1007/bf01644472 · Cited by 20
A Risk-Benefit Assessment of Zidovudine in the Prevention of Perinatal HIV Transmission
Newell, M., & Gibb, D. M. (1995) · Drug Safety · doi:10.2165/00002018-199512040-00007 · Cited by 20
Kim, D., Kim, Y., Gam, J., Kim, G., Lim, J., Lee, N., Kim, H., & Kim, K. H. (1996) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.5570330446 · Cited by 20
HIV life cycle and genetic approaches
Ratner, L. (1993) · Perspectives in Drug Discovery and Design · doi:10.1007/bf02171653 · Cited by 20
Fitzgibbon, J. E., Howell, R., Schwartzer, T. A., Gocke, D. J., & Dubin, D. T. (1991) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1991.7.265 · Cited by 20
Simberkoff, M. S., Hartigan, P. M., Hamilton, J. D., Day, P. L., Diamond, G. R., Dickinson, G. M., Drusano, G. L., Egorin, M. J., George, W. L., Gordin, F. M., et al. (1996) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199602010-00005 · Cited by 20
Enhancement of HIV-specific cytotoxic T lymphocyte responses by zidovudine (AZT) treatment
Dadaglio, G., Michel, F., Langlade‐Demoyen, P., Sansonetti, P. J., Chevrier, D., Vuillier, F., Plata, F., & Hoffenbach, A. (1992) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1992.tb06405.x · Cited by 20
Hoover, D. R., MUNTOZ, A., He, Y., Taylor, J. M. G., Kingsley, L., Chmiel, J. S., & Saah, A. J. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131920 · Cited by 20
Peters, M., Timm, U., Sch�rmann, D., Pohlel, H. D., & Ruf, B. (1992) · Journal of Molecular Medicine · doi:10.1007/bf00235533 · Cited by 20
Luque, F., Carúz, A., Pineda, J. A., Torres, Y., Larder, B. A., & Leal, M. (1994) · The Journal of Infectious Diseases · doi:10.1093/infdis/169.2.267 · Cited by 20
Self-citationSynthesis and anti-HIV Activity of a Series of 2-Indolinones and Related Analogues
Smallheer, J. M., Otto, M. J., Amaral-Ly, C., Earl, R. A., Myers, M. J., Pennev, P., Montefiori, D. C., & Wuonola, M. A. (1993) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029300400104 · Cited by 20
Anti-HIV Ermiasolides from Croton megalocarpus
Terefe, E. M., Okalebo, F., Derese, S., Langat, M. K., Mas‐Claret, E., Qureshi, K. A., Jaremko, M., & Muriuki, J. K. (2022) · Molecules · doi:10.3390/molecules27207040 · Cited by 19
IFN-λ Inhibits Drug-Resistant HIV Infection of Macrophages
Xu, W., Wang, H., Liu, M., Li, J., Zhou, R., Zhou, Y., Wang, Y., Zhou, W., & Ho, W. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00210 · Cited by 19
Long‐Term Treatment of Diseased, FIV‐Seropositive Field Cats with Azidothymidine (AZT)
Hart, S., & Nolte, I. S. (1995) · Zentralblatt für Veterinärmedizin Reihe A · doi:10.1111/j.1439-0442.1995.tb00392.x · Cited by 19
Silver, L. L. (2017) · Topics in medicinal chemistry · doi:10.1007/7355_2017_24 · Cited by 19
A Phase I Study of Ampligen in Human Immunodeficiency Virus-Infected Subjects
Armstrong, J. A., McMahon, D. K., Huang, X., Pazin, G. J., Gupta, P., Rinaldo, C. R., Schoenfeld, D., Gaccione, P., Tripoli, C. A., Bensasi, S., et al. (1992) · The Journal of Infectious Diseases · doi:10.1093/infdis/166.4.717 · Cited by 19
Lucarelli, M., Palitti, F., Carotti, D., Cianfriglia, M., Signoretti, C., Bozzi, A., & Ström, R. (1996) · FEBS Letters · doi:10.1016/0014-5793(96)01124-6 · Cited by 19
Quan, Y., Liang, C., Inouye, P., & Wainberg, M. A. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.24.5692 · Cited by 19
Nakashima, H., Inazawa, K., Ichiyama, K., Ito, M., Ikushima, N., Shoji, T., Katsuraya, K., Uryu, T., Yamamoto, N., Juodawlkis, A. S., et al. (1995) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029500600410 · Cited by 19
Simple colorimetric cell-cell adhesion assay using biotinylated lymphocytes
Pearce-Pratt, R., Phillips, D. M., & Bourinbaiar, A. S. (1991) · Journal of Immunological Methods · doi:10.1016/0022-1759(91)90366-n · Cited by 19
Martin, J. C., Hitchcock, M. J. M., Fridland, A., Ghazzouli, I., KAUL, S., Dunkle, L. M., Sterzycki, R., & Mansuri, M. M. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17824.x · Cited by 19
Hollander, H., Lifson, A. R., Maha, M. A., Slum, M. R., Rutherford, G. W., & Nusinoff-Lehrman, S. (1989) · The American Journal of Medicine · doi:10.1016/0002-9343(89)90721-3 · Cited by 19
Clinical Response to Dideoxyinosine in Patients with HIV Infection Resistant to Zidovudine
Bach, M. C. (1990) · New England Journal of Medicine · doi:10.1056/nejm199007263230414 · Cited by 19
Mohan, P., Singh, R. P., Wepsiec, J. P., Gonzalez, I., Sun, D. K., & Sarin, P. S. (1990) · Life Sciences · doi:10.1016/0024-3205(90)90471-3 · Cited by 19
Ohlsson‐Wilhelm, B. M., Cory, J. M., Kessler, H. A., Eyster, M. E., Rapp, F., & LANDAY, A. L. (1990) · The Journal of Infectious Diseases · doi:10.1093/infdis/162.5.1018 · Cited by 19
WALKER, R. E., Blaese, R. M., Davey, R. T., Falloon, J., Mullen, C. A., Polis, M. A., Finer, M. H., McGuire, B., Roberts, M. R., Zsebo, K. M., et al. (1996) · Human Gene Therapy · doi:10.1089/hum.1996.7.3-367 · Cited by 19
Hoover, D. R. (1995) · Drugs · doi:10.2165/00003495-199549010-00003 · Cited by 19
Occurrence of HIV-1 reverse transcriptase gene mutation at codon 215 in HIV-infected infants
Kamkamidze, G., Sullivan, T., & Charbonneau, T. T. (2001) · Journal of Clinical Virology · doi:10.1016/s1386-6532(01)00178-0 · Cited by 19
Gibson, R. M., Nickel, G. C., Crawford, M., Kyeyune, F., Venner, C. M., Nankya, I., Nabulime, E., Ndashimye, E., Poon, A. F. Y., Salata, R. A., et al. (2017) · Infectious Diseases of Poverty · doi:10.1186/s40249-017-0377-0 · Cited by 18
Developmental progress of CRISPR/Cas9 and its therapeutic applications for HIV‐1 infection
Deng, Q., Chen, Z., Shi, L., & Lin, H. (2018) · Reviews in Medical Virology · doi:10.1002/rmv.1998 · Cited by 18
HIV MDR is still a relevant issue despite its dramatic drop over the years
Armenia, D., Carlo, D. D., Flandre, P., Bouba, Y., Borghi, V., Forbici, F., Bertoli, A., Gori, C., Fabeni, L., Gennari, W., et al. (2019) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkz554 · Cited by 18
The role of backward mutations on the within-host dynamics of HIV-1
Kitayimbwa, J. M., Mugisha, J., & Saenz, R. A. (2012) · Journal of Mathematical Biology · doi:10.1007/s00285-012-0581-2 · Cited by 18
Mechanisms of resistance to xenobiotics in human therapy
Saves, I., & Masson, J. (1998) · Cellular and Molecular Life Sciences · doi:10.1007/s000180050170 · Cited by 18
Interactions of the HIV‐1 reverse transcriptase ‘AZT‐resistant’ mutant with substrates and AZT‐TP
Pokholok, D., Gudima, S. O., Есипов, Д. С., Dobrynin, V. N., Rechinsky, V. O., & Kochetkov, S. N. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81080-j · Cited by 18
Imidazo[1,5-b]Pyridazine-D4T Conjugates: Synthesis and Anti-Human Immunodeficiency Virus Evaluation
Renoud-Grappin, M., Fossey, C., Fontaine, G., LADUREE, D., Aubertin, A.-M., & Kirn, A. (1998) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029800900302 · Cited by 18
Yamaguchi, K., & Byrn, R. A. (1995) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/0167-4838(95)00167-1 · Cited by 18
Laethem, K. V., Witvrouw, M., Pannecouque, C. C., Remoortel, B. V., Schmit, J., Esnouf, R. M., Kleim, J., Balzarini, J. M., Desmyter, J., Clercq, E. D., et al. (2001) · AIDS · doi:10.1097/00002030-200103300-00003 · Cited by 18
New HIV protease inhibitors for drug-resistant viruses
Rusconi, S., & Viganò, O. (2005) · Therapy · doi:10.2217/14750708.3.1.79 · Cited by 18
Mathematical Models and the Design of Public Health Policy: Hiv and Antiviral Therapy
Gupta, S., Anderson, R. M., & May, R. M. (1993) · SIAM Review · doi:10.1137/1035001 · Cited by 18
Gong, Y., Marshall, D. R., Srinivas, R. V., & Fridland, A. (1994) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.38.7.1683 · Cited by 18
Risk of health care professionals acquiring HIV infection in Latin America
Cavalcante, N. J. F., Abreu, E., Fernandes, M. E. L., Richtmann, R., Piovesana, M., Yamada, F. T., & Carvalho, E. S. (1991) · AIDS Care · doi:10.1080/09540129108253078 · Cited by 18
Wells, K. H., & Poiesz, B. J. (1990) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/s0889-8545(21)00230-8 · Cited by 18
Challenges in the therapy of HIV infection
Yarchoan, R., Mitsuya, H., & Broder, S. E. (1993) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(93)90208-2 · Cited by 18
Buckheit, R. W., Decker, J. M., Hollingshead, M., Allen, L. B., Shannon, W. M., Janssen, P. A. J., & Chirigos, M. A. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.1097 · Cited by 18
Early HIV infection: to treat or not to treat?
Swart, A. M., Weller, I. V. D., & Darbyshire, J. H. (1990) · BMJ · doi:10.1136/bmj.301.6756.825 · Cited by 18
Akhtar, S., & Rossi, J. J. (1996) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/38.2.159 · Cited by 18
Prevention of Murine AIDS Development by (R)-9-(2-phosphonylmethoxypropyl)adenine
Suruga, Y., Makino, M., Okada, Y., Tanaka, H., Clercq, E. D., & Baba, M. (1998) · Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology · doi:10.1097/00042560-199808010-00002 · Cited by 18
Driscoll, J. S., Mayers, D., Bader, J., Weislow, O., Johns, D., & Buckheit, R. W. (1997) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029700800204 · Cited by 18
Antiviral Peptides with in vivo Activity: Development and Modes of Action
Gao, B., Zhao, D., Li, L., Cheng, Z., & Guo, Y. (2021) · ChemPlusChem · doi:10.1002/cplu.202100351 · Cited by 17
Mutants of feline immunodeficiency virus resistant to 2',3'-dideoxy-2',3'-didehydrothymidine
Zhu, Y. Q., Remington, K. M., & North, T. W. (1996) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.40.9.1983 · Cited by 17
Running a tightrope: Regulatory challenges in the development of antiretrovirals
Naeger, L. K., Struble, K. A., Murray, J. S., & Birnkrant, D. B. (2009) · Antiviral Research · doi:10.1016/j.antiviral.2009.07.016 · Cited by 17
Screening of the NIH Clinical Collection for inhibitors of HIV-1 integrase activity
Abrahams, S., Mosebi, S., Fish, M. Q., Papathanasopoulos, M. A., & Hewer, R. (2018) · South African Journal of Science · doi:10.17159/sajs.2018/20170324 · Cited by 17
Structure‐Function Studies of HIV Reverse Transcriptasea
Prasad, V. R., & Goff, S. P. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb17823.x · Cited by 17
Piras, G., Makino, M., & Baba, M. (1997) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1997.tb01937.x · Cited by 17
Nakashima, H., Ichiyama, K., Hirayama, F., Uchino, K., Ito, M., Saitoh, T., Ueki, M., Yamamoto, N., & Ogawara, H. (1996) · Antiviral Research · doi:10.1016/0166-3542(95)00903-5 · Cited by 17
Tewari, D., Notkins, A. L., & Zhou, P. (2003) · The Journal of Gene Medicine · doi:10.1002/jgm.336 · Cited by 17
Arts, E. J., Quiñones‐Mateu, M. E., & Albright, J. L. (1998) · Drug Resistance Updates · doi:10.1016/s1368-7646(98)80211-2 · Cited by 17
Kucera, L. S., Iyer, N., Puckett, S. H., Buckheit, R. W., Westbrook, L., TOYER, B. R., White, E. L., Decker, J. M., Shannon, W. M., CHEN, R. C.-S., et al. (1993) · AIDS Research and Human Retroviruses · doi:10.1089/aid.1993.9.307 · Cited by 17
Vaccaro, J. A., Singh, H., & Anderson, K. S. (1999) · Biochemistry · doi:10.1021/bi990945x · Cited by 17
Jeang, K.-T., Derse, D., Matocha, M. F., & Sharma, O. (1997) · Journal of Virology · doi:10.1128/jvi.71.9.6277-6278.1997 · Cited by 17
Rubio, A., Gómez-Cano, M., Puig, T., Leal, M., Pérez‐Olmeda, M., Ruiz, L., Clotet, B., Rey, C., Zamora, L., Xaus, N., et al. (1999) · Antiviral Therapy · doi:10.1177/135965359900400106 · Cited by 17
Lu, W., & Andrieu, J. (1992) · Journal of Virology · doi:10.1128/jvi.66.1.334-340.1992 · Cited by 17
Antiviral Properties of the HIV-1 Proteinase Inhibitor RO 31-8959
Galpin, S. A., Roberts, N. A., O'Connor, T., Jeffries, D. J., & Kinchington, D. (1994) · Antiviral chemistry & chemotherapy · doi:10.1177/095632029400500106 · Cited by 17
Abela, I. A., Scherrer, A., Böni, J., Yerly, S., Klimkait, T., Perreau, M., Hirsch, H. H., Furrer, H., Calmy, A., Schmid, P., et al. (2019) · Clinical Infectious Diseases · doi:10.1093/cid/ciz178 · Cited by 16
Parkin, N. T., Harrigan, P. R., Inzaule, S. C., & Bertagnolio, S. (2023) · PLOS Global Public Health · doi:10.1371/journal.pgph.0001948 · Cited by 16
Mechanisms of HIV-1 drug resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors
Nikolenko, G. N., Kotelkin, A., Oreshkova, S. F., & Ilyichev, A. A. (2011) · Molecular Biology · doi:10.1134/s0026893311010092 · Cited by 16
Schochetman, G. (1992) · Clinica Chimica Acta · doi:10.1016/0009-8981(92)90101-u · Cited by 16
The road to new antiviral therapies
Jerome, K. R. (2005) · Clinical and Applied Immunology Reviews · doi:10.1016/j.cair.2004.10.002 · Cited by 16
In vitro and in vivo toxicity of 2′,3′-dideoxycytidine in mice
Rossi, L., Brandi, G., Schiavano, G. F., Chiarantini, L., Albano, A., & Magnani, M. (1992) · Chemico-Biological Interactions · doi:10.1016/0009-2797(92)90066-t · Cited by 16
BIESERT, L., Adamski, M., Zimmer, G., Suhartono, H., Fuchs, J., Unkelbach, U., Mehlhorn, R. J., Hideg, K., Milbradt, R., & Rübsamen‐Waigmann, H. (1990) · Medical Microbiology and Immunology · doi:10.1007/bf00189609 · Cited by 16
HIV-1 genotypic resistance profile of patients failing antiretroviral therapy in Paraná, Brazil
Toledo, P. V. M., de Carvalho, D. S., Romagnoli, L., Marcinko, G., da Cunha, C. A., de Souza, M. N., Brindeiro, R., & Queiroz‐Telles, F. (2010) · The Brazilian Journal of Infectious Diseases · doi:10.1016/s1413-8670(10)70076-3 · Cited by 16
Immediate versus deferred zidovudine (AZT) in asymptomatic or mildly symptomatic HIV infected adults
Darbyshire, J. H., Foulkes, M. A., Peto, R., Duncan, W., Babiker, A. G., Collins, R., Hughes, M., Peto, T., & Walker, A. S. (2000) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002039 · Cited by 16
The V118I Mutation as a Marker of Advanced HIV Infection and Disease Progression
Zaccarelli, M., Tozzi, V., Lorenzini, P., Forbici, F., Narciso, P., Ceccherini‐Silberstein, F., Trotta, M. P., Bertoli, A., Liuzzi, G., Marconi, P., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200210 · Cited by 16
Field, H. J., & Goldthorpe, S. E. (1989) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(89)90069-2 · Cited by 16
Performance of drug resistance assays in testing HIV-1 non-B subtypes
Holguín, Á., Hertogs, K., & Soriano, V. (2003) · Clinical Microbiology and Infection · doi:10.1046/j.1469-0691.2003.00521.x · Cited by 16
Boulerice, F., Li, X. G., Lvovich, A., & Wainberg, M. A. (1991) · Journal of Virology · doi:10.1128/jvi.65.10.5589-5592.1991 · Cited by 16
Reversion from zidovudine resistance to sensitivity on cessation of treatment
Land, S., McGavin, K., Birch, C. J., & Lucas, R. (1991) · The Lancet · doi:10.1016/0140-6736(91)90727-7 · Cited by 16
Models of Viral Kinetics and Drug Resistance in HIV-1 Infection
Bonhoeffer, S. (1998) · AIDS Patient Care and STDs · doi:10.1089/apc.1998.12.769 · Cited by 16
Motura, M. I., Moroni, G. N., Teijeiro, S. A., Salomón, H., & Briñón, M. C. (2002) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1081/ncn-120003287 · Cited by 16
Design, characterization and testing of tRNA3Lys-based hammerhead ribozymes
Medina, M. F. C., & Joshi, S. (1999) · Nucleic Acids Research · doi:10.1093/nar/27.7.1698 · Cited by 16
Ijichi, K., Fujiwara, M., Hanasaki, Y., Watanabe, H., Katsuura, K., Takayama, H., Shirakawa, S., Sakai, S., Shigeta, S., & Konno, K. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.10.2337 · Cited by 16
Zidovudine for Early Human Immunodeficiency Virus (HIV) Infection: Who, When, and How?
Ruedy, J. R., Schechter, M. T., & Montaner, J. S. G. (1990) · Annals of Internal Medicine · doi:10.7326/0003-4819-112-10-721 · Cited by 16
Metadata
- Authors
- Larder, B. A., Darby, G., & Richman, D. D.
- Affiliations
- Wellcome Trust (GB)
- University of California San Diego (US)
- ORCID
- Richman, Douglas D.
- Venue
- Science
- Published
- 1989-03-31
- Volume
- 243
- Issue
- 4899
- Pages
- 1731-1734
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2086462809
- Cited by
- 1,559
- References
- 22
- Citations by year
- 2026: 4 · 2025: 7 · 2024: 3 · 2023: 10 · 2022: 12 · 2021: 8 · 2020: 9 · 2019: 12 · 2018: 6 · 2017: 13 · 2016: 16 · 2015: 10 · 2014: 21 · 2013: 13 · 2012: 16
- FWCI
- 157.06
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Heart, Lung, and Blood Institute (HB-6-7019)
- National Institute of Allergy and Infectious Diseases (AI-62548, AI-52578)
- Topics
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS drug development and treatment
- Life Sciences › Immunology and Microbiology › Virology › HIV Research and Treatment
- Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
- Keywords
- HIV drug resistance, zidovudine resistance, AIDS, AIDS-related complex, antiretroviral therapy, 2',3'-dideoxycytidine, phosphonoformate
- MeSH terms
- Acquired Immunodeficiency Syndrome, AIDS-Related Complex, Drug Resistance, HeLa Cells, HIV, Humans, Microbial Sensitivity Tests, Phosphonoacetic Acid, Viral Plaque Assay, Retroviridae Proteins, Virus Replication, Zidovudine, Dideoxynucleosides, Zalcitabine, HIV Core Protein p24, Foscarnet, Reverse Transcriptase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.